Management - Vicore Pharma

Ahmed Mousa

CEO

Ahmed Mousa has been CEO of Vicore Pharma since 2023 with an extensive background in business and corporate development, portfolio strategy, and entrepreneurial experience in the life sciences industry. Prior to joining Vicore, Ahmed was the Chief Business Officer & General Counsel of Pieris Pharmaceuticals where he played a key role in development of the company’s pipeline and execution of strategic collaborations with a range of pharmaceutical companies. Ahmed previously was an attorney representing biopharmaceutical companies in a range of matters at Covington & Burling and Kirkland & Ellis.

Shareholdings: View shareholding in link

Options: 800,000

Education: Undergraduate degrees in molecular biology and government from Cornell University and a master’s degree in biotechnology from Johns Hopkins University. Juris Doctor from Georgetown Law with honors.

Hans Jeppsson

CFO

Hans Jeppsson has been the CFO since 2017 and has a cross-disciplinary background in finance and medicine. He has previously worked as a biotech analyst at Danske Bank as well as within preclinical research at AstraZeneca R&D.

Shareholdings: View shareholding in link

Options: 240,000

Education: Ph.D. in Business Administration from the University of Gothenburg. After he obtained his Ph.D.-degree he conducted postdoctoral studies at the Haas School of Business at the UC Berkeley in the US. He also has a background in chemical engineering with a focus on biotechnology from Chalmers University of Technology.

Elin Rosendahl

VP Clinical Development

Elin Rosendahl has been VP Clinical development since 2020 with more than 20 years’ experience of managing global biopharmaceutical development programs and leading cross-functional teams. Solid experience of all phases of clinical drug development with focus on design of innovative and patient-focused paths to market, effective management of global, cross-functional teams and optimized collaborations with contract research organizations (CROs)

Shareholdings: View shareholding in link

Options: 200,000

Education: M.Sc, Pharmacy from Uppsala University

Rohit Batta

Chief Medical Officer

Rohit Batta has been the CMO since 2018 with over 20 years of experience as a medical doctor with an extensive background leading medical and clinical development teams whilst developing drugs for rare diseases. His previous roles include senior level positions within Cell and Gene Therapy at GlaxoSmithKline leading the clinical development and defining the clinical strategy for haemoglobinopathy gene therapy medicines. He also led the global medical and late stage clinical development teams to launch the world’s first gene therapy for patients with a paediatric rare disease. Rohit holds an MBBS from Kings College London where he is currently a Senior Visiting Lecturer.

Shareholdings: View shareholding in link

Options: 240,000

Education: MBBS from Kings College London and is a member of the Royal College of General Practitioners and the Faculty of Pharmaceutical Medicine.

Johan Raud

Chief Scientific Officer

Johan Raud has been the CSO since 2018 with more than 20 years of experience from heading research teams and managing drug discovery projects in both big pharma and startups. Johan gained his MD, PhD and Associate Professorship at Karolinska Institutet and Vanderbilt University.

Shareholdings: View shareholding in link

Options: 190,000

Education: MD PhD from the Karolinska Institute and Vanderbilt university, USA

Johanna Gräns

Program Director, early development

Johanna has been with Vicore since 2015 and has a Ph.D and expertise in pharmaceutical metabolism. She has extensive experience in preclinical interpretation and is responsible for drug development projects.

Shareholding: View shareholding in link

Options: 200,000

Education: MSc PhD

Jessica Shull

Director of Digital Therapeutics

Jessica Shull has been Director of Digital Therapeutics since 2021 with more than 20 years’ experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and internationally. In previous roles she worked on digital health best practices for the WHO and with the Digital Therapeutics Alliance she focused on digital therapeutic product integration, regulation, and policy.

Shareholdings: View shareholding in link

Options: 150,000

Education: MA, MSc, PhD candidate Biomedicine 2022

Nina Carlén

Chief Administrative Officer

Nina has been with Vicore since 2009 and has more than 20 years experience of working with communication and administration in the medical industry.

Shareholding: View shareholding in link
Options: 200,000
Education: Completed training in project management, PR, communication andgraphic design at, among others, Bergh’s School of Communication.

Åsa Magnusson

Chief Commercial Officer

Åsa Magnusson has been the CCO since 2021 with more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines. Her previous roles include leading cross-functional teams as General Manager at Arvelle and in different senior commercial roles at Alexion, expanding innovative antibody products and heading the commercial launch of Actelion’s pulmonary arterial hypertension (PAH) pharmaceuticals.

Shareholdings: View shareholding in link

Options: 150,000

Education: BBA and B2B marketing from Lund University

Mikael Nygård

VP Business Development

Mikael Nygård has been VP Business Development since 2021 with extensive experience from Business Development in the healthcare industry. He has led M&A and Corporate Development at the care provider Humana AB and has also worked in the global healthcare team at the strategy consulting firm Boston Consulting Group.

Shareholdings: View shareholding in link

Options: 141,000

Education: MSc Pharmacy, Uppsala University. PhD Neurobiology, Karolinska Institutet.

Caroline Spearpoint

Therapy Area Lead, rare lung disease

Caroline has been with Vicore since 2022 with over 20 years industry experience from pharmaceutical, biotech and management consultancy roles. Caroline has broad experience having worked in drug discovery, medical affairs, patient support, commercial operations, and strategic project management.

Caroline has overseen global project teams and the successful launch of several new medicines, with her strength in guiding cross functional teams to solve complex challenges.

Shareholdings: View shareholding in link

Options: 100,000

Education: BSc, Biological Sciences from University of Greenwich; PhD, Biochemistry from University of Kent.

Stine Furbo

Director Pharmaceutical Development

Stine Furbo has been with Vicore since 2021 and have more than 20 years of experience with pharmaceutical drug product development & product supply from both small biotech and big pharmaceutical companies. Stine has a substantial background in leading global teams and managing the drug product development program from early development stages towards market authorization and launch resulting in several drugs on market today.

Shareholdings: View shareholding in link

Options: 120,000

Education: Master of applied Chemical Engineering from the Danish Technical University (DTU), MMPI from Copenhagen Business School (CBS)